244 related articles for article (PubMed ID: 21649577)
1. Present and future of PI3K pathway inhibition in cancer: perspectives and limitations.
Ciraolo E; Morello F; Hirsch E
Curr Med Chem; 2011; 18(18):2674-85. PubMed ID: 21649577
[TBL] [Abstract][Full Text] [Related]
2. Phosphoinositide 3-kinase pathway inhibitors: pharmacology, metabolism & drug development.
Falasca M
Curr Med Chem; 2011; 18(18):2673. PubMed ID: 21649576
[No Abstract] [Full Text] [Related]
3. Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.
Poulsen A; Nagaraj H; Lee A; Blanchard S; Soh CK; Chen D; Wang H; Hart S; Goh KC; Dymock B; Williams M
J Chem Inf Model; 2014 Nov; 54(11):3238-50. PubMed ID: 25317974
[TBL] [Abstract][Full Text] [Related]
4. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
Wu P; Hu YZ
Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
[TBL] [Abstract][Full Text] [Related]
5. Recent developments of small molecule PI3K/mTOR dual inhibitors.
Liu YN; Wan RZ; Liu ZP
Mini Rev Med Chem; 2013 Dec; 13(14):2047-59. PubMed ID: 24195664
[TBL] [Abstract][Full Text] [Related]
6. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
7. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
Wang X; Ding J; Meng LH
Acta Pharmacol Sin; 2015 Oct; 36(10):1170-6. PubMed ID: 26364801
[TBL] [Abstract][Full Text] [Related]
8. Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.
Liu Y; Wan WZ; Li Y; Zhou GL; Liu XG
Oncotarget; 2017 Jan; 8(4):7181-7200. PubMed ID: 27769061
[TBL] [Abstract][Full Text] [Related]
9. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
10. 4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.
Liu KK; Bagrodia S; Bailey S; Cheng H; Chen H; Gao L; Greasley S; Hoffman JE; Hu Q; Johnson TO; Knighton D; Liu Z; Marx MA; Nambu MD; Ninkovic S; Pascual B; Rafidi K; Rodgers CM; Smith GL; Sun S; Wang H; Yang A; Yuan J; Zou A
Bioorg Med Chem Lett; 2010 Oct; 20(20):6096-9. PubMed ID: 20817449
[TBL] [Abstract][Full Text] [Related]
11. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.
Chen Y; Zhang L; Yang C; Han J; Wang C; Zheng C; Zhou Y; Lv J; Song Y; Zhu J
Bioorg Med Chem; 2016 Mar; 24(5):957-66. PubMed ID: 26819001
[TBL] [Abstract][Full Text] [Related]
12. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
13. Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.
Lv X; Ma X; Hu Y
Expert Opin Drug Discov; 2013 Aug; 8(8):991-1012. PubMed ID: 23668243
[TBL] [Abstract][Full Text] [Related]
14. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.
Li H; Zeng J; Shen K
Arch Gynecol Obstet; 2014 Dec; 290(6):1067-78. PubMed ID: 25086744
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and antitumor activity evaluation of PI3K inhibitors containing 3-substituted quinazolin-4(3H)-one moiety.
Zhang H; Xin MH; Xie XX; Mao S; Zuo SJ; Lu SM; Zhang SQ
Bioorg Med Chem; 2015 Dec; 23(24):7765-76. PubMed ID: 26652969
[TBL] [Abstract][Full Text] [Related]
16. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.
Mallon R; Feldberg LR; Lucas J; Chaudhary I; Dehnhardt C; Santos ED; Chen Z; dos Santos O; Ayral-Kaloustian S; Venkatesan A; Hollander I
Clin Cancer Res; 2011 May; 17(10):3193-203. PubMed ID: 21325073
[TBL] [Abstract][Full Text] [Related]
17. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
18. Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML.
Herschbein L; Liesveld JL
Blood Rev; 2018 May; 32(3):235-248. PubMed ID: 29276026
[TBL] [Abstract][Full Text] [Related]
19. PI3Ks-drug targets in inflammation and cancer.
Wymann M
Subcell Biochem; 2012; 58():111-81. PubMed ID: 22403076
[TBL] [Abstract][Full Text] [Related]
20. ATP-competitive inhibitors of mTOR: an update.
Schenone S; Brullo C; Musumeci F; Radi M; Botta M
Curr Med Chem; 2011; 18(20):2995-3014. PubMed ID: 21651476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
